preliminary results of 8- to 12-week double-blind trials indicate that etodolac therapy ( 200 mg twice a day ) compared favorably with piroxicam therapy ( 20 mg once a day ) and diclofenac therapy ( 50 mg three times a day ) as measured by improvement in scores of five efficacy assessments : number of painful joints , number of swollen joints , physician 's global assessment , patient 's global assessment , and pain intensity .
C0059865
etodolac
C0030193
painful